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Abstract. The tumor suppressor protein p53 is a transcription
factor that is frequently mutated in human cancers. In response
to DNA damage, unmutated or wild-type (wt) p53 protein is
stabilized and activated by post-transcriptional modifications
that enable it to induce either apoptosis or cell cycle arrest.
Using a yeast p53-dissociator assay, we identified MAGED2 as
a potential negative regulator of wt p53 activity. Subsequently,
using co-immunoprecipitation and reporter gene assays in
human cultured cells that are often adopted for functional
analysis of p53 we demonstrated that MAGED2 interacted
physically with p53 and modified its activity. Finally, we
were able to illustrate expression of both p53 and MAGED2
within the same subcellular compartment, i.e. either nucleus
or cytoplasm, in 2,682 human cancer tissue specimens using
a common cancer tissue microarray and antibodies against
MAGED2 and p53. The present results implicate MAGED2,
a novel protein, as a p53-dissociator.
Introduction
The tumor suppressor protein p53 is the single most important
protein to protect humans from cancer by inducing cell cycle
arrest or apoptosis after it has been activated by upstream stress
signals (1-5). Approximately 50% of all human cancers carry
p53 gene mutations (6); another 10-20% show inactivation
of the wt p53 protein either by high-risk human papilloma
virus E6, as in cervical cancers (7-10), or by overexpression
of MDM2, a physiological negative regulator of p53, as in
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sarcomas (11-15). The p53 status of the remaining 30-40% of
human cancers is currently poorly understood. A significant
subset of human tumors, such as neuroblastoma, melanoma
and breast cancer appear to have comparatively low rates of
p53 mutations and, thus, presumably, inactivate wt p53 via
interactions with cellular negative regulators of p53, known
as p53-dissociators (16,17). Indeed, neuroblastoma cells that
have wt p53 exhibit an impaired cell cycle arrest in response
to various genotoxic stimuli (18-20).
Using a well-validated p53-dissociator assay in yeast
(21,22), we screened a cDNA expression library derived from
a neuroblastoma (NB) cell line. The reason we opted to work
with that particular cell line was that NBs stand out by a
conspicuous absence of p53 mutations not only in primary
tumors but also in tumor-derived cell lines (23-25) and thus
protein-protein interactions or other unknown mechanisms
may disrupt wt p53 in such tumor cells. The protein that scored
the highest in our yeast p53-dissociator assay was Necdin
(NDN) a known p53-dissociator that has been shown to have
physical and functional interactions with p53 (26). We then
performed a search of protein databanks for NDN-related
protein sequences using the blastp program on the Internet
server of the National Center for Biotechnology Information
(NCBI). We found that NDN showed greatest amino acid
homology to the breast cancer associated gene-1 (BCG-1)
or more recently termed melanoma antigen, family D, 2
(MAGED2; NCBI accession # NM 014599). It is speculated,
based on the patterns of MAGE expression and observed
functions of NDN, that this gene family is involved in cell
cycle regulation (27). We therefore decided to investigate the
role of MAGED2 in human cells because its function was
unknown and via its homology with NDN could be another
novel p53-dissociator.
This report suggests that MAGED2 may be a novel p53dissociator not only in human cancer cells but also in human
cancer tissues and as such may have implications in cancer
management and prognosis.
Materials and methods
Chemicals and reagents. Enhanced chemiluminescence
Western blotting detection reagents were obtained from
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Amersham Pharmacia Biotech (Piscataway, NJ). The secondary
antibody was peroxidase-conjugated donkey antirabbit IgG
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Reagents
for immunohistochemistry (Dewax, peroxide block, power
block, link, horseradish peroxidase, 3,3-diaminobenzidine
tetrahydrochloride, hematoxylin, and buffers) were purchased
from BioGenex (San Ramon, CA).
Antibodies. Two polyclonal antibodies for MAGED2 were
generated by Genemed Synthesis Inc. (South San Fransisco,
CA) and Zymed Laboratories Inc. (South San Fransisco, CA)
respectively. Macvector software (Accelrys Inc., San Diego,
CA) was used to select an NH2-terminal peptide MAGED2
for generation of antipeptide antibodies. The sequence of the
peptide was H2N-AQSQENQDTRPK-COOH. Gameson-Wofs
software (DNASTAR, Inc., Madison, WI) was used to select
a COOH-terminal peptide for MAGED2 for generation of
antipeptide antibodies. The sequence of the peptide was H2NKDPKEWAAQYREAME-COOH. In parallel, two polyclonal
antibodies for NDN were generated by Genemed Synthesis Inc.
(South San Fransisco, CA). Gameson-Wofs software (Accelrys
Inc., San Diego, CA) was used to select both an NH2-terminal
and a COOH-terminal peptide of NDN for generation of
antipeptide antibodies. For the NH2-terminal of NDN, the
sequence of the peptide was H2N-SEQSKDLSDPNFAAECCOOH and for the COOH-terminal of NDN the sequence of
the peptide was H 2N-KKDPQAWPSRYREALC-COOH.
Peptides were synthesized, conjugated with keyhole limpet
hemocyanin and then injected into rabbits for antibody production. Antibodies against human p53 and p21 were purchased
from Dako Corporation (Carpinteria, CA).
SDS-PAGE and Western analysis. The mixtures were heated
at 100˚C for 3 min. Heated mixtures were then centrifuged
at 10,000 x g for 5 min to remove insoluble materials, and
supernatants were subjected to SDS-PAGE (10%). The proteins
were transferred to nitrocellulose membrane in transfer buffer
(96 mM glycine, 12 mM Tris base, and 15% methanol) using
a Semiphor Transphor Unit (Amersham Pharmacia Biotech,
San Francisco, CA) for 1 h. Immunoblot stains were performed
using the rabbit anti-NDN, anti-MAGED2 and standard goat
anti-rabbit immunoglobulin as primary and secondary antibodies, respectively. Detection was performed using enhanced
chemiluminescence reagents from Amersham Pharmacia
Biotech.
Immunohistochemistry. Immunohistochemistry was performed
using the streptavidin-biotin complex method, manually, as
described previously. For negative controls, slides were
incubated in the absence of the respective primary antibody
for MAGED2, p53 and p21 (phosphate-buffered saline or
PBS only). Slides were scanned with Nikon Eclips (E800)
using the MetaMorph imaging system and stored on a disk.
Common cancer tissue array set. The distribution of MAGED2,
NDN, p53 and p21 in human tumors was evaluated using
tissue arrays of common human cancers and normal tissues
purchased from the National Cancer Institute (Bethesda, MD).
Each tissue array slide contained 501 samples, each of which

was 2 mm in diameter and 4 μm thick. Tissue array slides
were mounted on siliconized glass slides and purchased ready
for use in immunohistochemistry as fourth generation (TARP4)
tissue microarrays. Slides containing no parenchymal cells
were not used for evaluation. Final analysis yielded 2,682
evaluable cases of tumor tissues, originating from 3,006 human
cancer tissue specimens representing 8 common human cancer
types including breast, colon, lung and lymphoma.
Semiquantitative assessment of MAGED2 and NDN. The
expression of MAGED2, NDN, p53 and p21 in situ was
evaluated by a semiquantitative scoring system. The intensity
of staining was scored as 0 (negative), 1 (weak), 2 (medium),
or 3 (strong). The extent of staining was scored as 0 (0%), 1
(1-25%), 2 (26-50%), 3 (51-75%), or 4 (76-100%), according
to the percentage of cells staining positive respectively for
MAGED2, NDN, p53 and p21. The sum of the intensity and
extent scores was used as the final staining score (0-7) for
MAGED2, NDN, p53 and p21 respectively. Tissues with a
final staining score of >2 were considered to be positive. A
final staining score of 2-3 was considered +, a final staining
score of 4-5 was considered ++, and a final staining score of
6-7 was considered +++.
cDNA libraries, plasmids and plasmid construction. The
screened cDNA expression libraries were derived from the
SKNSH NB cell line (LOT#81125; conc. 2.61 μg/μl; total
volume received 1.5 ml). For the construction of the cDNA
library, cDNAs were constructed using oligo(dT) NotI primers
and 5' SalI-MluI adaptors as described in the Superscript
plasmid system and ligated on SalI-NotI-digested p2.5 vector
(22). The following plasmids were used: pFLAG-CMV2
(Sigma), PG13-Luc (S.J. Baker), pRenilla (Promega), pFLAGSV40TAg (T. Wang and R.K. Brachmann), and pCMV-p53
(Clontech Laboratories). For experiments in mammalian cells
MAGED2 was cloned into pFLAG-CMV2 and subsequently
sequence-confirmed.
Studies in S.cerevisiae. Techniques for yeast maintenance
and p53-dissociator assay have been described (22). RBy333
resulted from the mating of two haploid strains, each containing
the p53 expression cassette integrated at the LYS2 locus and
the URA3 reporter construct. Also, RBy333 contains the
episome pES9 which is responsible for the expression of
E6-AP under the control of the inducible promoter MET25
on a LEU2 backbone.
Cell culture, transfection and reporter gene assays. A549
and H1299 cell lines were grown in high-glucose Dulbecco's
modified Eagle's medium with 10% fetal bovine serum.
Lipofectamine was used for all transfections. Reporter gene
assays were performed as previously described (21).
Co-immunoprecipitation (Co-IP) and immunoblotting (IB).
Cells were seeded at 1x106 mm plate and transfected with 3 μg
of total DNA. After 24 h, cells were washed with PBS, treated
with 1 mM dimethyl 13,3'-dithiobispropionimidate (2HCl)
(DTBP) for 20 min at room temperature and lysed with 500 μl
of ELB (50 mM HEPES, pH 7.2; 250 mM NaCl; 5 mM EDTA,
pH 8.0; 0.5% NP-40) containing protease and phosphatase
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Figure 1. The p53 dissociator assay in S. cerevisiae and p53-dissociators.
(A) For our NB library screen, cDNA expression library plasmids were
transformed into RBy333, transformants were then placed on plates selecting
for the plasmids (SC-His) and replica-plated (RP) after 3-5 days to plates
containing FOA (SC-His + 0.1% FOA). Over the next 2-7 days, FoaR clones
emerged which were then analyzed further as described previously (48). (B)
MAGED2 and NDN isolated as p53-dissociators in a p53-dissociator screen.
RBy333 containing NB cDNA library clones for MAGED2 and NDN were
replica-plated from SC-His to SC-His + 0.075% FOA at 30˚C and growth was
evaluated after 3 days. p2.5 was used as vector control.

inhibitors. After gentle rocking for 5 min, samples were
pipetted up and down 6-8 times for 10 min, centrifuged twice at
20800 x g for 10 min and exposed to FLAG-M2 beads (Sigma)
for 1-2 h (0-4˚C). Beads were washed three times with ELB
and once with PBS, spun down for 2 min at 500 x g, mixed
with 20-30 μl of loading buffer and boiled for 4 min prior to
standard immunoblotting analysis. To demonstrate the interaction of p53 and MAGED2, polyclonal anti-p53 antibody
conjugated to peroxidase (Boehringer Mannheim) was crosslinked to protein G-agarose (Santa Cruz Biotechnology) with
dimethyl pimelimidate (2HCl) (DMP). Normal sheep antimouse IgG-HRP (Amersham Life Sciences) cross-linked to
protein G-agarose was the negative control. Immunoblot
staining before Co-IP for detection of expression of FLAGtagged MAGED2 and p53 was performed using respectively
a mouse monoclonal anti-FLAG M5 antibody (Sigma-Aldrich)
and polyclonal anti-p53 antibody conjugated to peroxidase
(Boehringer Mannheim).
Statistical analysis. The correlation amongst nuclear readings
of proteins MAGED2, NDN, p53 and p21 as well as cytoplasmic readings of the above-mentioned proteins was assessed
using weighted κ statistics. All comparisons were considered
significant at P<0.05.
Results
Loss of wt p53 is probably the most common molecular
abnormality in human neoplasms. Inactivation by mutation is
not the sole mechanism of functional p53 disruption, but
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interactions with cellular proteins acting as p53-dissociators
may also affect p53 function. NB cells have wt p53 and an
impaired response to DNA damage. We, therefore, performed
a p53-dissociator screen of an NB cDNA expression library
using a yeast p53-dissociator assay. A total of 7.02x106 transformants yielded 112 FoaR clones that were confirmed after
single-colony purification. Of the 112 FoaR clones, 94 showed
plasmid dependency of the FoaR phenotype and 48 were FoaR
upon retransformation of Rby333 after plasmid rescue. They
represented five candidate proteins not previously connected
to p53, as well as NDN, a known p53-modifier, and 53BP1, a
known p53-coactivator. NDN scored the highest in our screen
(18 of 48 library plasmids in total, 10 independent clones;
Fig. 1) and showed the greatest amino-acid homology with
MAGED2. Since MAGED2, like NDN, was ubiquitous, we
decided to focus on MAGED2 whose function was unknown
and could possibly involve p53 interaction in neoplasms with
high rates of wt p53 such as breast, melanoma, and lymphoma.
We then obtained an expressed sequence tag (EST) clone
for full-length MAGED2 (accession no. NM 014599) and
constructed a mammalian expression plasmid, sequenceverified for FLAG-tagged full-length MAGED2. To determine
whether MAGED2 influences p53 activity in human cancer
cells we transiently transfected p53-positive A549 cells
with increasing amounts of FLAG-MAGED2. The results
consistently showed respectively no and 30-40% reduction of
p53 transcriptional activity in A549 cells transfected with
250 and 500 ng FLAG-MAGED2 (Fig. 2a). We also transiently
transfected p53-negative H1299 cells with p53 and increasing
amounts of FLAG-MAGED2. The results were interestingly
consistent with a 30-40% and 10% reduction of p53 transcriptional activity in H1299 cells transfected with 500 ng
and 1 μg FLAG-MAGED2 respectively (Fig. 2b). The protein
levels of p53 were unaffected by co-expression of FLAGMAGED2. The observed lesser degree of reduction of p53
transcriptional activity induced by the highest concentration
of FLAG-MAGED2 in H1299 cells may be cell-type specific
or indicate that the interaction between p53 and MAGED2
is transient and highly regulated by other factors. Our Co-IP
studies established that FLAG-MAGED2 interacted with
exogenous wt p53 and three different types of mutated p53 at
its DNA-binding site (DBS) suggesting that the DBS of p53
does not affect the interaction with MAGED2 (Fig. 2c).
Encouraged by the promising data in human cancer cells,
we next proceeded to evaluate the expression profile of
MAGED2 and NDN in human cancer tissue specimens.
Utilizing tissue microarray technology, we examined by
immunohistochemistry a total of 3,150 tumor specimens
from 8 different tumor types and 357 normal tissue specimens
from 29 different normal tissue types, 8 of which corresponded
to the 8 types of tumors, for the expression of MAGED2,
NDN, p53 and p21 (Table I). The p21 gene is a direct p53
response gene the expression of which, along with the
expression of p53, as measured by immunohistochemical
staining has traditionally been used to try to differentiate mutant
p53 tumors (p53-positive, p21-negative) from tumors with
activated wt p53, which also have increased expression of
p53-regulated genes (p53-positive, p21 positive). This approach
has been used in a plethora of studies to increase the predictive
value of p53 immunostaining for detection of the wt or

1205-1211

3/10/07

1208

16:53

Page 1208

PAPAGEORGIO et al: MAGED2

A

B

mutational status of p53 as a prognosticator of response to
chemotherapy in various human cancers. However, human
cancers in tissue microarrays represent unknown clinical
specimens consisting of mixed populations of cells with varying
cell cycle distributions which may contribute to variations
in the cytoplasmic or nuclear distribution of specifically
p21/cyclin/CDKs (28-30). For this reason, the question we
generated to be statistically tested for acceptance or rejection
of the Null Hypothesis examined whether p53 in conjunction
with its presumed p53-dissociator, MAGED2, was associated
in a statistically significant manner and within the same subcellular compartment with any variation of p21 levels. We
raised exactly the same hypothesis for NDN which is already
a known p53-dissociator. We used 2 antibodies for NDN and

C

Figure 2. A, analysis of p53 transcriptional activity in p53-positive A549
human cells using p53 reporter gene assays with luciferase. Increasing amounts
of an expression plasmid for FLAG-tagged full-length MAGED2 (250 and
500 ng) were transiently transfected into p53-positive A549 cells. Vector
control was used as negative control and SV40 large T antigen, a known p53
protein inhibitor, was used as positive control. Error bars represent standard
deviation for three independent experiments. The protein levels of p53 were
unaffected by co-expression of FLAG-MAGED2 as evidenced by immunoblotting performed with anti-p53 antibody after the cell lysates of the shown
reporter gene assay had been adjusted to control for Renilla luciferase activity.
Error bars represent standard deviation for three independent experiments.
B, analysis of p53 transcriptional activity in p53-negative H1299 human cells
using p53 reporter gene assays with luciferase. Increasing amounts of an
expression plasmid for FLAG-tagged full-length MAGED2 (250 and 500 ng)
were transiently co-transfected with the p53 expression plasmid (100 ng)
into p53-negative H1299 cells. Vector control was used as negative control
and SV40 large T antigen, a known p53 protein inhibitor, was used as
positive control. Error bars represent standard deviation for three independent
experiments. The protein levels of p53 were unaffected by co-expression of
FLAG-MAGED2 as evidenced by immunoblotting performed with anti-p53
antibody after the cell lysates of the shown reporter gene assay had been
adjusted to control for Renilla luciferase activity. C, co-immunoprecipitation
(IP) and immunoblotting (IB) assays. To demonstrate the interaction of p53
and MAGED2, FLAG-tagged MAGED2 (2 μg) was co-transfected transiently
with wt p53 (1 μg) and three different p53 mutants: R175H (1 μg), R273H
(1 μg) and G245S (1 μg). Immunoblot staining before IP for FLAG-tagged
MAGED2 was detected using a monoclonal anti-FLAG M5 antibody (SigmaAldrich); p53 was detected using anti-p53 polyclonal antibody BMG-1B1
(Boehringer Mannheim) conjugated to peroxidase raised against wt and mutant
p53. Immunoblot staining after IP was performed with anti-p53 polyclonal
antibody BMG-1B1 (Boehringer Mannheim) conjugated to peroxidase raised
against wt and mutant p53. It was evident that FLAG-MAGED2 interacted
with exogenous wt pt and three different types of cancer mutants suggesting
that the DNA-binding domain of p53 does not affect the interaction with
MAGED2. Vector control was used as negative control and SV40 large T-cell
antigen was used as a positive control.

MAGED2 respectively, raised against the N' and C' terminus
of each protein and determined their specificity by Western
blotting in H1299 cells. A κ-weighted statistics model showed
that tumor tissues with high levels of expression of nuclear
p53 and accompanying high levels of nuclear MAGED2 had
statistically significant variation, i.e. either very low or very
high nuclear p21 levels. We also demonstrated that tumor
tissues with high levels of expression of cytoplasmic p53
and accompanying high levels of cytoplasmic MAGED2 had
statistically significant variation, i.e. either very low or very
high cytoplasmic p21 levels (Fig. 3). Each one of the 2 antibodies against MAGED2 and each one of the 2 antibodies
against NDN produced similar statistically significant results;
interestingly, the antibody against the C' terminus of MAGED2
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Table I. Protein staining in nucleus and cytoplasm subdivided by sample tissue type.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Necdin ab
Necdin ab
MAGED2 ab
MAGED2 ab
against the
against the
against the
against the
p53
p21
NH2-terminal COOH-terminal NH2-terminal COOH-terminal
––––––––––– ––––––––––––– –––––––––––– ––––––––––––– –––––––––––– –––––––––––
Tissue type
L
H M
L
H
M
L
H
M
L
H
M
L
H M
L H M
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Brain cancer
N 18
1
6
6
13
6 11
9
5
13
9
3
15
6
4
21 0
4
C
18
1
9
10
12
8
2
20
21
0
21 0
Breast cancer

N
C

38
45

9
2

28

12
27

39
24

24

35
19

17
33

23

23
8

32
47

20

36
51

16
1

23

62
63

1
0

12

Colon cancer

N
C

58
52

0
6

17

17
18

39
38

19

30
18

19
31

26

36
13

21
44

18

40
59

20
1

15

63
62

0
1

12

Lung cancer

N
C

53
53

0
0

24
22

28
30

23

33
30

15
18

27

41
4

17
54

17

40
53

13
0

22

55
56

1
0

19

Lymphoma

N
C

46
47

1
0

3

12
24

35
23

3

27
30

16
13

7

27
13

20
34

3

43
48

5
0

2

47
47

0
0

3

Melanoma

N
C

18
16

0
2

7

1
1

13
13

11

13
9

5
9

7

11
1

9
19

5

15
19

6
2

4

20
20

0
0

5

Normal

N
C

35
33

0
2

16

22
11

11
22

18

30
20

2
12

19

32
1

2
33

17

37
35

0
2

14

46
45

0
1

5

Ovarian cancer

N
C

43
41

0
2

7

16
7

20
29

14

21
23

10
8

19

20
2

21
39

9

26
45

19
0

5

43
43

0
0

7

Prostate cancer

N
C

63
63

0
0

12

0
2

62
60

13

40
37

17
20

18

13
1

49
61

13

60
61

2
1

13

65
64

0
1

10

Summary

N 372 11 118 110 260 131 240 110 151 216 180 105 312 87 102 422 2 77
C 368 15
121 249
198 152
45 351
392
7
421 3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Sample sizes: brain, 25; breast, 75; colon, 75; lung, 75; lymphoma, 50; melanoma, 25; normal, 51; ovarian, 50; prostate, 75 (total, 501). L,
low staining; H, high staining; M, missing; N, nuclear staining; C, cytoplasm staining; ab, antibody.

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

generated highly statistically significant results. The correlation of data between both antibodies against MAGED2 was
significant.
Discussion
The present study demonstrates that MAGED2 can, like its
homologue, NDN, be placed into a group of p53-interacting
proteins. Both MAGED2 and NDN belong to the MAGE
superfamily (31) the precise cellular role of which remains
unclear. The clearest evidence of a physiological role for the
MAGE genes has come from NDN which appears to be playing
a role in the development or maintenance of hypothalamic
neurons by enhancing p53-induced cell cycle arrest yet,
intriguingly, inhibiting p53-mediated apoptosis (26,32,33). In
other words, NDN facilitates cell cycle arrest but promotes
cell survival of nerve cells. Our observed lesser degree of
reduction of p53 transcriptional activity induced by the highest
concentration of FLAG-MAGED2 in H1299 cells may be, as
stated above, cell-type specific; it may also suggest that the
interaction between p53 and MAGED2 may be labile and

Figure 3. Immunohistochemical detection of p53 and MAGED2 in human
cancer tissues. Shown are representative photomicrographs of sections of
breast cancer (1A, 1B) and colon cancer (2A, 2B) depicting nuclear (1A,
2A) and cytoplasmic staining (1B, 2B). Original magnification x200.
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may involve other binding factors depending on the cellular
microenvironment as it occurs between NDN and p53. Our
results are in agreement with the findings by Taniura et al
(26) suggesting that, like NDN, MAGED2 binds p53 at a
domain other than its DBS. Given the effects of NDN on cell
cycle progression and its ability to regulate p53, it will be
important to determine whether MAGED2 has similar cellular
roles. MAGED2, contrary to the predominantly brain-specific
NDN, is expressed in human lung, brain, pancreas, skeletal
muscle, heart, placenta, and kidney (34). Although progress
on the cellular roles of MAGE proteins is beginning to
accelerate, study in this area is nascent. Analysis of the
structures of members of the MAGE superfamily does not
permit a definite conclusion concerning the mechanism of
the selective expression profile of some members of the
MAGE superfamily in tumors (31). Indeed, NDN and many
of the MAGED family members are broadly expressed during
development and several are highly expressed in various forms
of cancer (35-40). It is not known yet whether expression
of NDN or MAGED genes has any effect on cellular transformation or tumor progression, but studies from diverse areas
now suggest important roles for both NDN and MAGED
proteins in cell survival, cell cycle progression and apoptosis
(40). The high degree of conservation of certain domains
among all MAGE members suggests a common general
function served by these domains. Defining binding partners
such as p53 of family members such as the ubiquitously
expressed MAGED2 will no doubt provide insights into the
fundamental cellular roles of all family members not only in
tumorigenesis but also in neurogenetic disease.
Tissue microarray technology was used to provide a ‘total
body scan’ of our protein of interest. This technology enables
researchers not only to have access to valuable human
specimens for specific research but also to perform more
efficient studies than possible with conventional slides (41).
Although the assumption must be made that the 2.0-mmdiameter specimen is representative of the tissue of interest,
tissue arrays offer an important step to providing context and
data large enough for a statistical analysis like ours. What our
human cancer tissue microarray data suggests is that, in a range
of human cancer tissues, when MAGED2 co-localizes with
p53 in the nucleus or cytoplasm it is linked with a significant
modification of p53 activity within that same subcellular
compartment. Of course, it is important to realize that IHC
studies designed to yield meaningful results are very timeconsuming and moreover, difficult to interpret for the following
reasons. Negative IHC for p53 can indicate wt p53 status or
deleted p53 genes. Positive IHC for p53 is commonly but not
always associated with p53 mutations (16) some of which may
act as transdominant negative mutations in p53-heterozygous
tumor cells, i.e. as tumorigenic through gain-of-function.
The function of p21 in growth arrest after DNA damage in
response to activated p53 has recently been overshadowed by
its role in concomitant apoptosis prevention, mitogenesis and
tumorigenesis (42). Lastly, MAGED2, like NDN, may enhance
p53-mediated growth suppression via a p21-independent
pathway in certain cancers where low rather than high levels
of p21 can be observed (26). Thus, the statistically significant
variation of p21 levels observed in our tissue microarrays may
be due to either a labile interaction between p53 and MAGED2

as indicated by our findings in human cancer cells or the fact
that the molecular biology of p21 remains for the most part
unknown. Indeed, p21 can have a p53-independent role as
it has been described in the development of at least some
neoplasms (43). Despite the imperfections described above of
interpretation of IHC studies, we would like to state explicitly
that if wt p53 protein accumulates to levels detectable by
IHC, it is almost inescapable to conclude that this p53 protein
does not act as wt protein since high levels of functional p53
protein seem to be incompatible with growth. Thus, we can
conclude that protein-protein interactions like the one we are
proposing may disrupt wt p53 function in such tumor cells. It
is beyond the scope of this article to review the plethora of
IHC studies on p53 as a predictor of response to chemotherapy
in various human cancers.
In summary, our data suggest that MAGED2, like its
homologue NDN, interacts physically with p53 and impairs
its transcriptional activity in human cancer cells. This interaction may also be observed in human cancer tissues as
statistically significant correlations between p53 and its p53dissociator (NDN or MAGED2) have been made only when
p53 and its dissociator are co-localized within the same subcellular compartment across all cancer types tested. The human
MAGE genes and proteins constitute an intriguing gene family
under increasing attention because of the emerging roles of
two of the family's members, MAGED1 and Necdin in cell
cycle progression, apoptosis and neurogenetic disease (36,44).
As far as we know this is the first study that suggests a
physiological cellular role for MAGED2 which is considered
the ancestor of all the MAGE genes (34,45). Recently, Harper
et al (46) identified a novel MAGED2 antisense RNA transcript
in human tissues which may potentially have important
implications for future studies examining MAGED2 expression
patterns in cancer and normal tissues. Future study in this
area should focus on, among other methods, antisense and
small molecule inhibitor techniques to transiently inhibit
MAGED2 in animal studies and subsequently clinical trials.
Restoration of p53 function has already been demonstrated to
lead tumor regression in vivo (47). These results support
efforts to treat human cancers by way of pharmacological
reactivation of p53 which at the present time holds much
promise.
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